Opening Asia for Russia

Indian vaccine Covaxin protects against coronavirus by 77.8%

13.11.2021 109 просмотров

The Covaxin vaccine has demonstrated a high level of efficacy against COVID-19 during the third phase of clinical trials.


Scientists have completed the third phase of clinical trials of the Indian vaccine Covaxin, according to the results of which it provided protection against coronavirus infection in approximately 77.8% of patients. The scientists' findings were published in an article in the Lancet.

“The Covaxin vaccine has demonstrated a high level of efficacy against COVID-19 in phase III clinical trials. The vaccine was generally very well tolerated by patients, we did not record any serious problems with the safety of its use, ”the researchers write.

The Covaxin (BBV152) vaccine is being developed by the Indian company Bharat Biotech. Its first clinical trials began in July 2020. It is a classic vaccine based on a weakened version of the SARS-CoV-2 virus, which does not pose a threat to the human body, but at the same time contributes to the development of an immune response to the real COVID-19 pathogen.

The last, third phase of clinical trials Covaxin started last October. Almost 26 thousand people took part in them, who received two doses of the vaccine with an interval of a month. The main part of the trials was completed in the middle of this summer.

Observations carried out by Indian scientists showed that two injections of the vaccine protected about 77.8% from the development of all overt forms of coronavirus infection and about 65% from the SARS-delta strain. CoV-2. Including all cases of COVID-19 without visible symptoms, the first indicator decreased to 63.6%. A similar decline was also characteristic of older people - the Covaxin vaccine protected about 66% of them from infection with all variations of the coronavirus. At the same time, scientists note that they have not recorded any dangerous side effects that threaten the life of vaccinated patients, with the exception of one case of the development of a hemorrhagic rash. Biotech, who led the team of scientists involved in the research, Covaxin vaccine is slightly inferior to RNA vaccines in terms of effectiveness, but at the same time it is able to protect a significant proportion of the population from infection with COVID-19 and about 93% of patients from severe forms of infection. This allows it to be used to contain the spread of coronavirus at the level of large human populations.

Новости партнёров